氨甲环酸治疗创伤性脑损伤的最佳剂量:随机对照试验的系统评价与网状Meta分析
本研究为系统评价与网状Meta分析,检索5个数据库至2024年5月,纳入10项RCT、共11237例创伤性脑损伤(TBI)患者,比较不同剂量氨甲环酸(TXA)与对照的疗效。结果显示,安慰剂组死亡率高于2 g TXA弹丸注射组(RR 1.53,95%CI 1.08-2.17),1 g弹丸+1 g维持TXA组死亡率亦高于2 g弹丸组(RR 1.44,95%CI 1.02-2.03);各组不良神经功能结局及血管闭塞事件无显著差异。作者据此推荐2 g TXA,但指出2 g弹丸数据仅来自单一研究,需进一步研究以得出确切结论。
要点
- 纳入10项RCT、11237例TBI患者,比较TXA不同剂量与对照的死亡率及神经功能结局。
- 安慰剂组死亡率高于2 g TXA弹丸组(RR 1.53,95%CI 1.08-2.17)。
- 1 g弹丸+1 g维持TXA组死亡率高于2 g弹丸组(RR 1.44,95%CI 1.02-2.03)。
- 各组不良神经功能结局及血管闭塞事件无显著差异。
- 作者推荐2 g TXA,但2 g弹丸数据仅来自单一研究,需进一步研究。
适用人群与场景
- 年龄大于1个月的创伤性脑损伤(TBI)患者(纳入标准)。
处置流程与药物剂量
- 2 g TXA弹丸注射(原文推荐剂量,数据来自单一研究)。
- 1 g TXA弹丸注射后1 g维持治疗(原文对比方案)。
研究设计与关键结果
- 系统评价与网状Meta分析,纳入10项RCT、共11237例TBI患者,检索5个数据库至2024年5月。
- 主要结局:安慰剂组死亡率高于2 g TXA弹丸组(RR 1.53,95%CI 1.08-2.17)。
- 主要结局:1 g弹丸+1 g维持TXA组死亡率高于2 g弹丸组(RR 1.44,95%CI 1.02-2.03)。
- 次要结局:各组不良神经功能结局及血管闭塞事件无显著差异。
证据类型、等级与局限
- 证据类型:系统评价与网状Meta分析(频率学方法,采用GRADE工作组的评价方法),证据等级Level III。
- 局限:2 g TXA弹丸的数据来自单一研究,需进一步研究以得出确切结论(原文Conclusion)。
对床旁实践的改变
- 作者认为,基于网状Meta分析结果推荐2 g TXA用于TBI患者,因安慰剂及1 g弹丸+1 g维持方案死亡率更高。
- 作者指出,2 g TXA弹丸的数据仅来自单一研究,需进一步研究以得出确切结论。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Tranexamic acid (TXA) has been used to treat traumatic brain injury (TBI); however, no definitive conclusions have been drawn regarding its effectiveness or dosage. This study evaluated the optimal TXA dose for treating TBI using a network meta-analysis (NMA).
METHODS: Five databases were searched for peer-reviewed randomized controlled trials (RCTs) published from inception to May 2024. The inclusion criteria were as follows: (1) RCTs, (2) patients older than 1 month with TBI, (3) interventions of TXA and control, (4) primary outcomes of mortality and poor neurological outcomes and secondary outcomes of vascular occlusive events, and (5) full-text peer-reviewed articles. Two reviewers independently screened and extracted the data and assessed the risk of bias. Frequency-based NMA was performed using the Grading of Recommendations, Assessment, Development, and Evaluation working-group approach.
RESULTS: We included 10 RCTs comprising 11,237 patients with TBI. Placebo showed higher mortality compared with that of a 2-g bolus of TXA (risk ratio, 1.53; 95% confidence interval, 1.08-2.17). Higher mortality was observed with a 1-g bolus of TXA followed by 1-g maintenance TXA compared with that of a 2-g bolus of TXA (risk ratio, 1.44; 95% confidence interval, 1.02-2.03). No significant differences in poor neurological outcomes or vascular occlusive events were observed between the treatment groups.
CONCLUSION: Placebo and a 1-g bolus followed by 1-g maintenance TXA were associated with higher mortality rates than those of a 2-g bolus of TXA. No difference in vascular occlusive events was observed with either treatment, indicating that our NMA recommends 2 g of TXA. However, the data for the 2-g bolus of TXA were from a single study, and further research is needed to draw definitive conclusions.
LEVEL OF EVIDENCE: Systematic Review/Meta-Analysis; Level III.
参考来源
- Utsumi S, Kawakami A, Amemiya Y, et al. Optimal dose of tranexamic acid in traumatic brain injury: Systematic review and network meta-analysis of randomized controlled trials. J Trauma Acute Care Surg. 2024. PMID: 39652152. doi:10.1097/TA.0000000000004500
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。